Squarepoint
VTGN icon

Squarepoint’s VistaGen Therapeutics VTGN Stock Holding History

Squarepoint’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-140,000
Closed -$413K – 5492
2024
Q4 		$413K Hold
140,000
– – ﹤0.01% 3904
2024
Q3 		$421K Buy
+140,000
New +$478K ﹤0.01% 3225

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Squarepoint's VTGN Position: Q1 2025 in Review

Squarepoint sold out of VistaGen Therapeutics (VTGN) in Q1 2025, closing a stake of 107,744 shares — an estimated $318K sold.

Squarepoint first reported a position in VTGN in Q1 2022 and held it in 5 quarters. The position peaked at $318K in Q4 2024. 48 funds tracked by Wall St. Rank hold VTGN as of Q1 2025.

  • Squarepoint reported no remaining VistaGen Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Squarepoint sold 107,744 VistaGen Therapeutics shares in Q1 2025, an estimated $318K.
  • Squarepoint first reported a position in VistaGen Therapeutics in Q1 2022 and held it in 5 quarters.
  • Squarepoint's VistaGen Therapeutics position peaked at $318K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.